- Previous Close
1,283.60 - Open
1,259.00 - Bid --
- Ask --
- Day's Range
1,211.50 - 1,277.50 - 52 Week Range
1,211.50 - 1,800.00 - Volume
356,301 - Avg. Volume
778,051 - Market Cap (intraday)
141.695B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-34.17 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India and internationally. The company provides end-to-end CDMO services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. OneSource Specialty Pharma Limited was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. The company was incorporated in 2007 and is based in Bengaluru, India.
www.onesourcecdmo.comRecent News: ONESOURCE.NS
View MorePerformance Overview: ONESOURCE.NS
Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONESOURCE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONESOURCE.NS
View MoreValuation Measures
Market Cap
141.54B
Enterprise Value
147.03B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
82.42
Price/Book (mrq)
35.81
Enterprise Value/Revenue
85.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.34%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
10.92B
Net Income Avi to Common (ttm)
-1.57B
Diluted EPS (ttm)
-34.17
Balance Sheet and Cash Flow
Total Cash (mrq)
338.2M
Total Debt/Equity (mrq)
30.42%
Levered Free Cash Flow (ttm)
--